 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...496497498499500501502503504505506507508» |
- ||||| Bexxar (iodine I 131 tositumomab) / GSK, Rituxan (rituximab) / Roche
New P1/2 trial, Metastases: Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma (clinicaltrials.gov) - Nov 30, 2011
P1/2, N=96, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- New P2 trial, Combination therapy: ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Nov 27, 2011
P2, N=35, Recruiting, Sponsor: Vejle Hospital
- sorafenib / Generic mfg.
New P2 trial, Metastases: Sorafenib VS TACE in HCC Patients With Portal Vein Invasion (clinicaltrials.gov) - Nov 27, 2011
P2, N=40, Recruiting, Sponsor: Seoul National University Hospital
- Trial termination: A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response (clinicaltrials.gov) - Nov 22, 2011
P1, N=2, Terminated, Sponsor: University of Chicago
Recruiting --> Terminated; PI no longer affiliated with institution; only 2 subjects enrolled
- Enrollment change: A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response (clinicaltrials.gov) - Nov 22, 2011
P1, N=2, Terminated, Sponsor: University of Chicago
Recruiting --> Terminated; PI no longer affiliated with institution; only 2 subjects enrolled N=15 --> 2
- Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Roche
Enrollment open, Combination therapy: Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). (clinicaltrials.gov) - Nov 21, 2011
P1/2, N=63, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
N=15 --> 2 Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche
Enrollment open: S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Nov 20, 2011
P2, N=180, Recruiting, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment closed: PBIC: Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens (clinicaltrials.gov) - Nov 20, 2011
P=N/A, N=50, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Campath (alemtuzumab) / Sanofi
Enrollment change, IO biomarker: CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas (clinicaltrials.gov) - Nov 16, 2011
P1, N=24, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Recruiting --> Active, not recruiting N=34 --> 24
- | New P2 trial, Metastases: ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer (clinicaltrials.gov) - Nov 14, 2011
P2, N=56, Recruiting, Sponsor: Susanne Crocamo
- Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Enrollment closed, Metastases: Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function (clinicaltrials.gov) - Nov 13, 2011
P2, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=34 --> 24 Recruiting --> Active, not recruiting
- ||||||| Trial completion, Combination therapy: BIG 02/98 Docetaxel - Breast Cancer (clinicaltrials.gov) - Nov 8, 2011
P3, N=2887, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Enrollment closed: PLRG4: First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. (clinicaltrials.gov) - Nov 2, 2011
P3, N=250, Active, not recruiting, Sponsor: Polish Lymphoma Research Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Clinical: International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry (clinicaltrials.gov) - Nov 1, 2011
P=N/A, N=125, Recruiting, Sponsor: Children's Hospitals and Clinics of Minnesota
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery (clinicaltrials.gov) - Nov 1, 2011
P2, N=50, Completed, Sponsor: University of Washington
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Matulane (procarbazine hydrochloride) / Leadiant Biosci
New P2 trial: Prospective Study on HIV-related Hodgkin Lymphoma (clinicaltrials.gov) - Oct 31, 2011
P2, N=130, Recruiting, Sponsor: Harlachinger Krebshilfe e.V.
- Enrollment closed: Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer (clinicaltrials.gov) - Oct 27, 2011
P2, N=56, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Active, not recruiting --> Completed No longer recruiting --> Active, not recruiting
- | Oncaspar liquid (pegaspargase) / Servier
Clinical: Treatment of Acute Lymphoblastic Leukemia in Children (clinicaltrials.gov) - Oct 24, 2011
P3, N=800, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
No longer recruiting --> Active, not recruiting N=544 --> 800
- || Mepact (mifamurtide) / Takeda
New P2/3 trial, Metastases: ISG/OS-2: ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma (clinicaltrials.gov) - Oct 23, 2011
P2/3, N=225, Recruiting, Sponsor: Italian Sarcoma Group
- |||||||||| Retuxira (rituximab biosimilar) / 3SBio
New P3 trial, Combination therapy: Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma (clinicaltrials.gov) - Oct 17, 2011
P3, N=278, Completed, Sponsor: Shanghai CP Guojian Pharmaceutical Co.,Ltd.
- Rituxan (rituximab) / Roche
New P2 trial, Post-transplantation: Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD) (clinicaltrials.gov) - Oct 17, 2011
P2, N=70, Terminated, Sponsor: Charite University, Berlin, Germany
- | Decadron (dexamethasone) / Merck (MSD), Oncaspar liquid (pegaspargase) / Servier
New P2 trial: NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 11, 2011
P2, N=72, Recruiting, Sponsor: St. Jude Children's Research Hospital
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed: REAL07: Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Oct 11, 2011
P2, N=49, Active, not recruiting, Sponsor: Fondazione Italiana Linfomi ONLUS
N=544 --> 800 Recruiting --> Active, not recruiting
- mitomycin / Generic mfg., doxorubicin hydrochloride / Generic mfg., sorafenib / Generic mfg.
Enrollment closed, Combination therapy, Surgery: Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Oct 10, 2011
P1, N=11, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Herceptin (trastuzumab) / Roche
New P3 trial: This is an early stage breast cancer trial for women who have low expression of a biological protein called Her 2.Patients will have either node positive disease or high risk node negative disease. Patients will be assigned to receive chemotherapy alone or chemotherapy +Trastuzumab in a completely random fashion. (EUDRACT) - Oct 5, 2011
P3, N=300, Ongoing, Sponsor: ICORG-the All Ireland co-operative Oncology Research group
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P2 trial: Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Oct 5, 2011
P2, N=33, Recruiting, Sponsor: Chonbuk National University Hospital
- | Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Enrollment closed, Metastases: The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP (clinicaltrials.gov) - Oct 3, 2011
P2, N=30, Active, not recruiting, Sponsor: Mahidol University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change, Metastases: Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma (clinicaltrials.gov) - Oct 2, 2011
P2, N=4, Completed, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting N=10 --> 4
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma (clinicaltrials.gov) - Oct 2, 2011
P2, N=4, Completed, Sponsor: St. Jude Children's Research Hospital
N=10 --> 4 Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Enrollment change: Treatment and Natural History Study of Lymphomatoid Granulomatosis (clinicaltrials.gov) - Sep 28, 2011
P=N/A, N=85, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=60 --> 85
- Campath (alemtuzumab) / Sanofi
Enrollment closed: Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas (clinicaltrials.gov) - Sep 28, 2011
P2, N=31, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=60 --> 85 Recruiting --> Active, not recruiting
- vinorelbine tartrate / Generic mfg., doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Trial completion, Combination therapy: Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors (clinicaltrials.gov) - Sep 28, 2011
P1, N=29, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Completed
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Enrollment open: S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Sep 26, 2011
P2, N=155, Recruiting, Sponsor: Southwest Oncology Group
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
New P3 trial, Combination therapy, Metastases: TH-CR-406: A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 22, 2011
P3, N=620, Active, not recruiting, Sponsor: Threshold Pharmaceuticals
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer (clinicaltrials.gov) - Sep 14, 2011
P=N/A, N=41, Completed, Sponsor: University of Washington
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients (clinicaltrials.gov) - Sep 13, 2011
P=N/A, N=23, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=18 --> 23
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients (clinicaltrials.gov) - Sep 13, 2011
P=N/A, N=23, Completed, Sponsor: M.D. Anderson Cancer Center
N=18 --> 23 Active, not recruiting --> Completed
- ||| cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
New P2/3 trial: Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients (clinicaltrials.gov) - Sep 12, 2011
P2/3, N=40, Completed, Sponsor: Dexa Medica Group
- Zolinza (vorinostat) / Merck (MSD)
Enrollment open, Combination therapy: Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) (clinicaltrials.gov) - Sep 11, 2011
P1/2, N=30, Recruiting, Sponsor: University Hospital Freiburg
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- New P2 trial, Combination therapy: An Open-Label Phase II Study of the Safety and Efficacy of Doxorubicin and Cyclophosphamide in Combination with Bortezomib, Lenalidomide, and Dexamethasone for Treatment of Patients with Newly Diagnosed Multiple Myeloma (EUDRACT) - Sep 4, 2011
P2, N=30, Ongoing, Sponsor: Vejle Hospital
- cisplatin / Generic mfg., cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma (clinicaltrials.gov) - Aug 31, 2011
P2, N=140, Completed, Sponsor: University of Arkansas
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 25, 2011
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| MK-4214 (filgrastim biosimilar) / Merck (MSD)
New P3 trial: A Phase III Randomized, Double-Blind, Active-Controlled Clinical Trial to Study the Efficacy and Safety of MK-4214 (filgrastim) and Neupogen (EUDRACT) - Aug 24, 2011
P3, N=32, Ongoing, Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
- ||||| seribantumab (MM-121) / Elevation Oncology
New P2 trial: A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer (clinicaltrials.gov) - Aug 18, 2011
P2, N=200, Active, not recruiting, Sponsor: Merrimack Pharmaceuticals
- pevonedistat (MLN4924) / Takeda, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Biomarker, New P1/2 trial: MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma (clinicaltrials.gov) - Aug 10, 2011
P1/2, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Biomarker, New P2 trial, Combination therapy, Metastases: A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) (clinicaltrials.gov) - Aug 9, 2011
P2, N=100, Active, not recruiting, Sponsor: Genentech
- |||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open, Combination therapy: A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) (clinicaltrials.gov) - Aug 9, 2011
P3, N=1400, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., capecitabine / Generic mfg.
New P2/3 trial: AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer (clinicaltrials.gov) - Aug 8, 2011
P2/3, N=300, Recruiting, Sponsor: Peking Union Medical College Hospital
- bortezomib / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial termination, Metastases: Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer (clinicaltrials.gov) - Aug 7, 2011
P2, N=4, Terminated, Sponsor: University of Wisconsin, Madison
Not yet recruiting --> Recruiting Suspended --> Terminated; no additional funding
- | Rituxan (rituximab) / Roche
New P2 trial: S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Aug 7, 2011
P2, N=180, Recruiting, Sponsor: Southwest Oncology Group